Teleflex Incorporated (TFX)
| Market Cap | 5.99B +3.8% |
| Revenue (ttm) | 2.25B +110.9% |
| Net Income | -1.03B |
| EPS | -23.41 |
| Shares Out | 42.37M |
| PE Ratio | n/a |
| Forward PE | 15.34 |
| Dividend | $1.36 (0.96%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 837,975 |
| Open | 140.10 |
| Previous Close | 138.98 |
| Day's Range | 138.92 - 142.05 |
| 52-Week Range | 100.18 - 145.00 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 154.00 (+8.92%) |
| Earnings Date | Nov 5, 2026 |
About TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and col... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for TFX stock is "Buy." The 12-month stock price target is $154.0, which is an increase of 8.92% from the latest price.
News
Teleflex announces FDA Breakthrough Device Designation for Freesolve RMS
Teleflex (TFX) announced that the U.S. FDA has granted Breakthrough Device Designation for its Freesolve Resorbable Magnesium Scaffold for percutaneous coronary intervention. To qualify for a BDD, dev...
Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthr...
Teleflex Announces Third Quarter 2026 Earnings Conference Call Information
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on ...
Teleflex price target lowered to $142 from $150 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Teleflex (TFX) to $142 from $150 and keeps a Hold rating on the shares as part of a broader research…
Teleflex price target lowered to $140 from $145 at Mizuho
Mizuho lowered the firm’s price target on Teleflex (TFX) to $140 from $145 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices and…
Teleflex completes patient enrollment in BIOMAG-LL Clinical Study
Teleflex (TFX) Iannounced the successful completion of patient enrollment in the BIOMAG-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve Resorbable Magnesium Scaffold...
Enrollment Completed in BIOMAG™-LL Clinical Study Evaluating Longer Lengths for Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Cli...
Teleflex’s Arrowg+ard Technology reduces CLABSI risk in peer-reviewed study
Teleflex (TFX) announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters, or CVCs, protected with Arrowg+ard ...
Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Jou...
BofA upgrades Teleflex to Buy, says growth potential not appreciated
As previously reported, BofA analyst Travis Steed upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145. With a new management team and better…
Teleflex upgraded to Buy from Neutral at BofA
BofA upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145.
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective...
Teleflex to showcase Dynetic-35 Stent System at CIRSE 2026
Teleflex (TFX) announced it will showcase technologies at CIRSE 2026 in Copenhagen. Among the featured technologies will be the Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System. This technol...
Teleflex to showcase technologies at CIRSE 2026 in Copenhagen
Teleflex (TFX) Incorporated announced it will showcase technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technol...
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen,...
Teleflex price target raised to $158 from $145 at UBS
UBS raised the firm’s price target on Teleflex (TFX) to $158 from $145 and keeps a Neutral rating on the shares. The firm updated its model post the Q2 earnings…
Teleflex price target raised to $150 from $143 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Teleflex (TFX) to $150 from $143 and keeps a Hold rating on the shares after its Q2 earnings beat. A…
Teleflex price target raised to $155 from $150 at Raymond James
Raymond James raised the firm’s price target on Teleflex (TFX) to $155 from $150 and keeps an Outperform rating on the shares. Teleflex delivered solid Q2 results, raised EPS guidance,…
Teleflex Earnings Call Transcript: Q2 2026
Q2 saw strong Vascular and Surgical growth, offset by Interventional integration delays, leading to lowered revenue guidance but higher EPS outlook. Strategic divestitures and capital returns are progressing, with innovation milestones achieved. 2026 is a transition year, with significant improvement expected in 2027.
Teleflex Earnings release: Q2 2026
Teleflex released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Teleflex Slides: Q2 2026
Teleflex has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Teleflex Quarterly report: Q2 2026
Teleflex has published its Q2 2026 quarterly earnings report on August 6, 2026.
Teleflex raises 2026 adjusted EPS view 6.90-$7.20 from $6.25-$6.55
2026 EPS consensus $6.67. Lowers 2026 revenue growth view to 13.4%-14.4% from 14.4%-15.4% from 2025 revenue of $1.98B, consensus $2.29B.
Teleflex reports Q2 adjusted EPS $1.76, consensus $1.28
Reports Q2 cont-op revenue $570.3M, consensus $559.57M. “We delivered a strong Q2, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to st...
Teleflex Announces Quarterly Dividend
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...